Cancer type
NSCLC and SCLC are treated differently because they often differ in growth pattern, biology, spread and response to therapy.
Lung Cancer Education · Treatment Options · Biomarker-Guided Care
Lung Cancer Treatment Education
Lung cancer treatment depends on the cancer type, stage, biomarker profile, tumor location, lung function, overall health and patient-specific clinical factors. Treatment may involve local therapies, systemic therapies or a combination of several approaches.
Educational information only. This page does not provide diagnosis, medical advice
or treatment recommendations. Treatment decisions must be made with qualified
healthcare professionals.
Surgery
Radiation
Immunotherapy
Targeted Therapy
How lung cancer treatment is planned
Treatment planning begins with understanding the diagnosis, histological type, stage and molecular features of the tumor. The treatment plan may differ between non-small cell lung cancer and small cell lung cancer.
Stage of disease
Early-stage disease may be approached differently from locally advanced or metastatic disease.
Biomarker profile
Molecular and immune markers can help identify tumor features such as EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, HER2 and PD-L1.
Local treatments and systemic treatments
Lung cancer care often combines different treatment categories. Local treatments focus on a tumor area, while systemic treatments circulate through the body.
L
Local treatment
Surgery and radiation therapy mainly treat a defined tumor area or nearby regional disease.
S
Systemic treatment
Chemotherapy, targeted therapy and immunotherapy can act throughout the body.
C
Combination treatment
Some treatment plans use combinations such as chemotherapy plus radiation, surgery plus systemic therapy, or immunotherapy plus chemotherapy.
Treatment Strategy
Local
Systemic
Stage
Biomarkers
Non-small cell lung cancer treatment education
NSCLC treatment depends strongly on stage and molecular profile. Treatment can include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy or combined approaches.
Earlier-stage NSCLC
Some earlier-stage tumors may be treated with surgery, radiation therapy or other local treatments. Additional chemotherapy, immunotherapy or targeted therapy may be considered depending on clinical features.
Locally advanced NSCLC
Treatment may involve combined approaches such as chemotherapy with radiation therapy, sometimes followed by immunotherapy depending on the clinical setting.
Metastatic NSCLC
Treatment often depends on biomarker results and may involve targeted therapy, immunotherapy, chemotherapy, anti-angiogenic therapy, radiation for symptom control or clinical trial options.
Small cell lung cancer treatment education
SCLC often grows and spreads quickly, so treatment commonly uses systemic therapy. Radiation therapy may also be used depending on stage and clinical assessment.
Limited-stage SCLC
Treatment often involves chemotherapy and radiation therapy. In selected uncommon cases, surgery may be considered when disease is found very early.
Extensive-stage SCLC
Treatment commonly involves systemic therapy such as chemotherapy with immunotherapy, along with supportive care and symptom-directed radiation when needed.
Biomarker-guided treatment concepts
Biomarker testing can identify molecular or immune features of lung cancer. These results may help clinicians understand whether a tumor has specific treatment-relevant biology.
EGFR
EGFR mutations can define a molecular subtype of NSCLC and are commonly evaluated in lung adenocarcinoma.
ALK
ALK rearrangements can identify tumors driven by fusion kinase signaling.
ROS1
ROS1 rearrangements are another molecular alteration assessed in selected NSCLC cases.
KRAS
KRAS alterations are important in oncogenic signaling and molecular classification.
MET / RET / NTRK / HER2
Expanded molecular profiling may evaluate additional treatment-relevant alterations.
PD-L1
PD-L1 expression is used to describe immune checkpoint biology and may be considered during immunotherapy planning.
Care Plan
Symptoms
Nutrition
Breathing
Fatigue
Support
Managing side effects and quality of life
Every treatment can have possible side effects. Supportive care helps manage symptoms and maintain quality of life before, during and after treatment.
Breathing symptoms
Shortness of breath, cough or airway symptoms may require specialist support.
Fatigue
Fatigue is common and may be related to cancer, treatment, anemia, sleep or nutrition.
Nutrition and weight
Loss of appetite or weight loss may require nutritional support.
Emotional support
Education, counseling and patient support services can help people cope with treatment.
Clinical trials and treatment research
Clinical trials study new treatment strategies, combinations, biomarkers, resistance mechanisms and supportive-care approaches. A healthcare team can explain whether a trial may be relevant for a specific diagnosis and stage.
Research continues to improve lung cancer care
Lung cancer treatment in simple terms
Treatment can be understood by asking four key questions: What type of lung cancer is it? What stage is it? What biomarkers are present? What is the person’s overall health and treatment goal?
What are the main treatments for lung cancer?
Main treatment categories include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, supportive care and clinical trials.
Why are biomarkers important?
Biomarkers can reveal molecular or immune features of the tumor. In some cases, this information helps clinicians select more specific treatment approaches.
Is treatment the same for everyone?
No. Lung cancer treatment is individualized based on tumor type, stage, biomarkers, symptoms, lung function, overall health and patient preferences.
FAQ: Lung Cancer Treatment Education
Clear answers to common questions about lung cancer treatment categories, biomarkers and care planning.
What are the main treatment options for lung cancer?
Main options include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, supportive care and clinical trials. The best approach depends on lung cancer type, stage and clinical context.
Is lung cancer treatment different for NSCLC and SCLC?
Yes. Non-small cell lung cancer and small cell lung cancer often have different treatment pathways because they differ in biology, spread pattern and response to therapy.
What is targeted therapy in lung cancer?
Targeted therapy uses medicines designed to act on specific molecular alterations or pathways in cancer cells, such as EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2 or KRAS-related biology.
What is immunotherapy in lung cancer?
Immunotherapy helps the immune system recognize or attack cancer cells. Many lung cancer immunotherapies involve immune checkpoint pathways such as PD-1, PD-L1 or CTLA-4.
Why is biomarker testing important?
Biomarker testing helps describe tumor biology and may identify molecular or immune features that are relevant to treatment planning.
Is this page medical advice?
No. This page is educational only and does not replace medical consultation, diagnosis or treatment planning by qualified healthcare professionals.
Scientific References
Authoritative sources used to support the treatment education content on this page.
- National Cancer Institute. Non-Small Cell Lung Cancer Treatment PDQ.
- American Cancer Society. Treating Non-Small Cell Lung Cancer.
- American Cancer Society. Treatment Choices for Non-Small Cell Lung Cancer by Stage.
- Cancer Research UK. Treatment options for non-small cell lung cancer.
- National Cancer Institute. Small Cell Lung Cancer Treatment PDQ.